Metylfenidat Actavis

Methylphenidate hydrochloride, the active ingredient in Metylfenidat Actavis, is a central nervous system stimulant presented as an oral tablet for oral use. It is prescribed to manage attention deficit hyperactivity disorder and narcolepsy in children, adolescents, and adults, helping improve focus and reduce excessive daytime sleepiness.

GNH USA supplies Metylfenidat Actavis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics and research institutions worldwide.

Methylphenidate acts on central nervous system pathways involved in attention and wakefulness.

- Attention deficit hyperactivity disorder (children): improves attention and reduces hyperactivity in school settings. - Attention deficit hyperactivity disorder (adults): enhances concentration and productivity in work environments. - Narcolepsy: decreases daytime sleepiness and cataplexy episodes.

Methylphenidate may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Insomnia: difficulty falling or staying asleep. - Decreased appetite: reduced food intake leading to weight loss. - Headache: mild to moderate cranial pain. - Irritability: increased mood swings or agitation.

Serious or Rare Side Effects: - Cardiovascular events: hypertension, arrhythmia, or myocardial infarction. - Psychosis or severe agitation: new or worsening psychiatric symptoms. - Allergic reaction: rash, swelling, or anaphylaxis.

When prescribing methylphenidate, clinicians should observe several safety considerations.

- Assess cardiovascular status: obtain baseline blood pressure and heart rate. - Monitor psychiatric symptoms: watch for mood changes, psychosis, or mania. - Avoid use in known hypersensitivity: discontinue if allergic reaction occurs. - Use caution in seizure disorders: evaluate risk of seizure exacerbation. - Store at room temperature: keep in original container, protect from moisture and light.

Methylphenidate can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - MAO inhibitors: risk of hypertensive crisis. - Other CNS stimulants: increased cardiovascular stimulation. - Certain antidepressants (tricyclics, SSRIs): may raise plasma methylphenidate levels.

Moderate Interactions (Monitor Closely): - Antihypertensives: possible reduction in blood‑pressure‑lowering effect. - Anticonvulsants: may lower methylphenidate concentrations. - Acidifying agents: can decrease drug absorption.